title: Immunoregulation with levamisole in children with frequently relapsing steroid responsive nephrotic syndrome.
abstract: The immunological and clinical effects of levamisole were studied in 10 children with frequently relapsing steroid responsive nephrotic syndrome (SRNS). The efficacy of the drug was tested during remission of the disease with all patients on alternate day steroid therapy. The lymphocyte proliferative response to phytohemagglutinin (PHA), concanavalin-A (Con-A) and pokeweed mitogen (PWM) were normal. The Con-A induced suppressor T-lymphocyte activity of 7 patients was low before treatment with levamisole 8 +/- 3.7% and increased to normal values during therapy 34 +/- 6%; p less than 0.001 (control 32 +/- 5%). In these 7 children prednisolone dosage could be decreased significantly or discontinued altogether (44.1 +/- 5.3%). Patients without immunoregulatory abnormalities did not respond to levamisole. In 3 out of 4 children tested the percentage of OKT8+ cells rose during levamisole therapy from 19.7 +/- 2.1 to 37 +/- 2.3 (p less than 0.001), thus correcting the elevated pre-treatment OKT4+/OKT8+ ratio from 3.1 +/- 0.2 to 1.5 +/- 0.2; p less than 0.001 (control 1.47 +/- 0.2). These data support the hypothesis that abnormal immunoregulation may play a role in the pathogenesis of SRNS. Treatment with levamisole can be useful in some patients with the frequently relapsing form of the disease.
authors.affiliation: Division of Pediatric Nephrology, Shaare Zedek Medical Center, Jerusalem, Israel.
authors.forename: R
authors.initials: R
authors.lastname: Drachman
authors.forename: M
authors.initials: M
authors.lastname: Schlesinger
authors.forename: U
authors.initials: U
authors.lastname: Alon
authors.forename: J
authors.initials: J
authors.lastname: Mor
authors.forename: A
authors.initials: A
authors.lastname: Etzioni
authors.forename: H
authors.initials: H
authors.lastname: Shapira
authors.forename: M
authors.initials: M
authors.lastname: Ohali
authors.forename: A
authors.initials: A
authors.lastname: Drukker
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002699:Chlorambucil / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000276:immunology; D011239:Prednisolone / Q000627:therapeutic use; D012074:Remission Induction
chemical_list: D002699:Chlorambucil; D007978:Levamisole; D003520:Cyclophosphamide; D011239:Prednisolone